BR112022025264A2 - Anticorpos terapêuticos anti-emapii humanizados - Google Patents

Anticorpos terapêuticos anti-emapii humanizados

Info

Publication number
BR112022025264A2
BR112022025264A2 BR112022025264A BR112022025264A BR112022025264A2 BR 112022025264 A2 BR112022025264 A2 BR 112022025264A2 BR 112022025264 A BR112022025264 A BR 112022025264A BR 112022025264 A BR112022025264 A BR 112022025264A BR 112022025264 A2 BR112022025264 A2 BR 112022025264A2
Authority
BR
Brazil
Prior art keywords
emapii
humanized anti
therapeutic antibodies
antibodies
therapeutic
Prior art date
Application number
BR112022025264A
Other languages
English (en)
Inventor
W P Hay Douglas
E Berezovsky Suzanne
Knight David
Huang Kexin
K Wang Jordon
Original Assignee
Allinaire Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allinaire Therapeutics Llc filed Critical Allinaire Therapeutics Llc
Publication of BR112022025264A2 publication Critical patent/BR112022025264A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS TERAPÊUTICOS ANTI-EMAPII HUMANIZADOS. A presente invenção refere-se a anticorpos monoclonais que se ligam ao polipeptídeo II ativador de monócitos endoteliais e a métodos de tratamento usando os mesmos.
BR112022025264A 2020-06-29 2021-06-28 Anticorpos terapêuticos anti-emapii humanizados BR112022025264A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045687P 2020-06-29 2020-06-29
PCT/US2021/039389 WO2022005979A1 (en) 2020-06-29 2021-06-28 Humanized anti-emap ii therapeutic antibodies

Publications (1)

Publication Number Publication Date
BR112022025264A2 true BR112022025264A2 (pt) 2023-01-03

Family

ID=79314890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025264A BR112022025264A2 (pt) 2020-06-29 2021-06-28 Anticorpos terapêuticos anti-emapii humanizados

Country Status (14)

Country Link
US (1) US20230287095A1 (pt)
EP (1) EP4171634A1 (pt)
JP (1) JP2023533514A (pt)
KR (1) KR20230029774A (pt)
CN (1) CN115996753A (pt)
AU (1) AU2021299452A1 (pt)
BR (1) BR112022025264A2 (pt)
CA (1) CA3181077A1 (pt)
CL (1) CL2022003771A1 (pt)
CO (1) CO2023000343A2 (pt)
IL (1) IL299548A (pt)
MX (1) MX2022015874A (pt)
PE (1) PE20230442A1 (pt)
WO (1) WO2022005979A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170929A2 (en) * 2011-06-08 2012-12-13 Indiana University Research And Technology Corporation Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
US10132815B2 (en) * 2013-02-13 2018-11-20 Indiana University Research & Technology Corporation Methods of diagnosing, treating and monitoring diabetic retinopathy
CN105658799A (zh) * 2013-10-07 2016-06-08 普雷斯蒂奇生物制药私人有限公司 用于抗体表达的双顺反子表达载体以及用其生产抗体的方法
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators

Also Published As

Publication number Publication date
CL2022003771A1 (es) 2023-05-26
IL299548A (en) 2023-02-01
WO2022005979A1 (en) 2022-01-06
AU2021299452A1 (en) 2023-02-02
CN115996753A (zh) 2023-04-21
KR20230029774A (ko) 2023-03-03
CO2023000343A2 (es) 2023-04-17
CA3181077A1 (en) 2022-01-06
JP2023533514A (ja) 2023-08-03
MX2022015874A (es) 2023-03-03
EP4171634A1 (en) 2023-05-03
PE20230442A1 (es) 2023-03-08
US20230287095A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2020014773A2 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
MX2019012868A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190235A1 (ru) Антитела к cd33 и способы их применения
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
ECSP22055004A (es) Anticuerpos anti?mertk y m?todos de uso de los mismos
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112022023117A2 (pt) Constructos de anticorpos de domínio único neutralizantes de sars-cov2
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
BR112022025264A2 (pt) Anticorpos terapêuticos anti-emapii humanizados
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение
CO2021008755A2 (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
EA202190954A1 (ru) Гуманизированное моноклональное антитело против n-укороченного бета-амилоида
BR112022018629A2 (pt) Anticorpos anti-muc1-sea
EA202191677A1 (ru) Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения
EA202190071A1 (ru) Антитела к pd-1 и их применение
EA202191139A1 (ru) АНТИТЕЛА К EpCAM, АКТИВИРУЕМЫЕ АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И ИХ ПРИМЕНЕНИЕ
MX2023008029A (es) Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas.